Sanziguben polysaccharides inhibit diabetic nephropathy through NF-κB-mediated anti-inflammation

Abstract Background Sanziguben polysaccharides (SZP) are large amounts of classical Chinese medicines from (SZGB). Moreover, SZGB is a widely applied compound prescription for diabetic nephropathy (DN) treatment, but the role still unclear. This study initially explores mechanism SZP in treatment DN. Methods The high-fat diet plus streptozotocin injections were used to replicate DN models male C57BL/6 mice. mice divided into five groups: mice, treated with SZP(1.01 or 2.02 g/kg), decoction(4.7 and metformin (300 mg/kg). HG LPS TNFα stimulated human tubule epithelial (HK-2) cells establish an vitro model (100 200 μg/mL). Results was found comprise sugar, protein, uronic acid. Furthermore, alleviated progression inflammation vivo by inhibiting expression NF-κB. Conclusions NF-κB plays critical development induced STZ HG. can attenuate NF-κB‐mediated nephropathy, improve through anti-inflammation.